- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 42
- States / cities
- Sun City, Arizona • Glendale, California • Inglewood, California + 38 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, Prostaglandin analogue
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension
- Interventions
- Voyager DSLT
- Device
- Lead sponsor
- The Eye Institute of West Florida
- Other
- Eligibility
- Not listed
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Largo, Florida
- Conditions
- Glaucoma, Ocular Hypertension, Eye Disease
- Interventions
- AMA0076, Placebo
- Drug
- Lead sponsor
- Amakem, NV
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 9
- States / cities
- Artesia, California • Inglewood, California • Petaluma, California + 6 more
- Conditions
- Open Angle Glaucoma (OAG), Ocular Hypertension (OH)
- Interventions
- Travoprost
- Combination Product
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Kenosha, Wisconsin
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- RKI983
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Timeline
- Started 2007
- U.S. locations
- 5
- States / cities
- Artesia, California • Rochester, New York • Charlotte, North Carolina + 2 more
- Conditions
- Primary Open Angle Glaucoma
- Interventions
- Not listed
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,540 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2022
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • La Jolla, California • New York, New York
- Conditions
- Open-angle Glaucoma, Diabetic Retinopathy
- Interventions
- GlaucoHealth, GlaucoSelect, Placebo
- Drug
- Lead sponsor
- The New York Eye & Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Glaucoma; Drugs, Normal Tension Glaucoma, Primary Open-angle Glaucoma
- Interventions
- Timolol Maleate, Brimonidine Tartrate
- Drug
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Open-angle Glaucoma (OAG)
- Interventions
- CycloPen Micro-Interventional Cyclodialysis System, CycloPen Micro-Interventional Cyclodialysis System Post Cataract
- Procedure
- Lead sponsor
- Iantrek, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 10
- States / cities
- Newport Beach, California • Cape Coral, Florida • Atlanta, Georgia + 7 more
- Conditions
- Open Angle Glaucoma, Ocular Hypertension, Glaucoma, Open Angle, Pseudo-exfoliative, Pigment Dispersion Syndrome, Glaucoma
- Interventions
- Selective Laser Trabeculoplasty, Neodymium:Yttrium Aluminum Garnet (YAG) laser
- Procedure · Device
- Lead sponsor
- Temple University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Wilmington, Delaware • Thorndale, Pennsylvania
- Conditions
- Glaucoma, Open-Angle
- Interventions
- Methazolamide 25 MG, Methazolamide 50 MG
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- Travoprost (0.004%), Latanoprost (0.005%)/Timolol (0.5%)
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Glaucoma, Glaucoma, Open-Angle, Glaucoma; Drugs, Droopy Eyelid, Ptosis, Glaucoma, Primary Open Angle
- Interventions
- brimonidine tartrate ophthalmic solution 0.025%, sterile balanced saline solution
- Drug · Other
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2036
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Primary Open Angle Glaucoma
- Interventions
- Glaucoma Surgery, InnFocus MicroShunt
- Procedure · Device
- Lead sponsor
- InnFocus Inc.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 732 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 24
- States / cities
- Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 21 more
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- OT-730 ophthalmic solution, timolol maleate ophthalmic solution, OT-730 placebo
- Drug
- Lead sponsor
- Othera Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 5
- States / cities
- Artesia, California • Roswell, Georgia • Charlotte, North Carolina + 2 more
- Conditions
- Glaucoma, Primary Open Angle
- Interventions
- ELIOS Procedure
- Device
- Lead sponsor
- Elios Vision, Inc.
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 20
- States / cities
- Glendale, Arizona • Petaluma, California • Fort Collins, Colorado + 16 more
- Conditions
- Sturge-Weber Syndrome (SWS), Glaucoma, Glaucoma Congenital, Ocular Hypertension
- Interventions
- QLS-101ophthalmic solution 1%, QLS-101ophthalmic solution 2%
- Drug
- Lead sponsor
- Qlaris Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- NCX 470 0.065% (initial phase of trial), Latanoprost 0.005% (initial phase of trial), NCX 470 0.1% (initial phase of trial), NCX 470 0.1% (remainder of trial), Latanoprost 0.005% (remainder of trial)
- Drug
- Lead sponsor
- Nicox Ophthalmics, Inc.
- Industry
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 691 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Primary Open-Angle Glaucoma
- Interventions
- Stents, Laser, Laser Trabeculoplasty
- Device · Procedure
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 35 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 9
- States / cities
- Glendale, Arizona • Fayetteville, Arkansas • Hemet, California + 6 more
- Conditions
- Primary Open-angle Glaucoma
- Interventions
- Questionnaires
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Primary Open Angle Glaucoma or Ocular Hypertension
- Interventions
- Netarsudil ophthalmic solution 0.02%, Artificial tears
- Drug
- Lead sponsor
- East Coast Institute for Research
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Glaucoma, Open Angle or Ocular Hypertension
- Interventions
- brinzolamide 1% ophthalmic suspension, Azopt 1%
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Open Angle Glaucoma, Ocular Hypertension, Pseudoexfoliation Syndrome
- Interventions
- Travatan, Azopt, Alphagan P
- Drug
- Lead sponsor
- Hermann Eye Center
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2005
- U.S. locations
- 21
- States / cities
- Los Angeles, California • Hamden, Connecticut • Gainesville, Florida + 14 more